Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Other Non-Current Liabilities (2016 - 2025)

ImmunityBio (IBRX) has disclosed Other Non-Current Liabilities for 12 consecutive years, with $19.7 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities rose 6082.45% to $19.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19.7 million through Dec 2025, up 6082.45% year-over-year, with the annual reading at $19.7 million for FY2025, 6082.45% up from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $19.7 million at ImmunityBio, up from $18.3 million in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $118.8 million in Q4 2023, with the low at $288000.0 in Q1 2022.
  • Average Other Non-Current Liabilities over 5 years is $15.8 million, with a median of $891000.0 recorded in 2021.
  • The sharpest move saw Other Non-Current Liabilities skyrocketed 25889.06% in 2023, then plummeted 99.73% in 2024.
  • Over 5 years, Other Non-Current Liabilities stood at $905000.0 in 2021, then crashed by 49.5% to $457000.0 in 2022, then surged by 25889.06% to $118.8 million in 2023, then tumbled by 99.73% to $319000.0 in 2024, then soared by 6082.45% to $19.7 million in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $19.7 million, $18.3 million, and $710000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.